Trials / Completed
CompletedNCT06729580
Risk-Targeted Behavioural Activation for the Management of Treatment-Resistant Depression.
Risk-Targeted Behavioral Activation: a Novel Approach to the Management of Treatment-Resistant Depression.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- McGill University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Depression is the leading cause of disability worldwide. Major Depressive Disorder (MDD) is the most common diagnosis made for individuals seeking treatment for depression. Although a wide range of treatments have been developed for the treatment of MDD, a significant proportion of patients fail to respond. This study examined the effectiveness of a 10-week behavioural activation intervention for individuals with treatment-resistant depression.
Detailed description
Objective: The purpose of the present study was to examine the acceptability and impact of a standardized 10-week risk-targeted behavioral activation (RTBA) intervention as an augmentation strategy in the clinical management of treatment-resistant depression (TRD). Methods: The study sample consisted of 118 individuals with TRD, who were currently absent from work and referred to an occupational rehabilitation service. The RTBA intervention was a 10-week standardized program consisting of weekly visits with a trained clinician. The objectives of treatment included symptom reduction, resumption of important life activities (including return to work) and improvement in quality of life. Measures of depression, perceived injustice, and catastrophic thinking were completed pre-, mid- and post-treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Behavioural Activation | 10-week standardized behavioural activation program. |
Timeline
- Start date
- 2022-01-05
- Primary completion
- 2023-10-30
- Completion
- 2023-10-30
- First posted
- 2024-12-11
- Last updated
- 2024-12-11
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06729580. Inclusion in this directory is not an endorsement.